The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: GVC Down 18% As Chiefs Sell 3 Million Shares

Fri, 08th Mar 2019 10:50

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------Fresnillo, up 1.7%. The Mexican gold miner was tracking spot gold price higher, quoted at USD1,295.07 an ounce, up from USD1,285.30 at the London equities close Thursday. Mid-cap Egyptian miner Centamin was up 1.8%.----------GlaxoSmithKline, up 0.8%. The drugmaker said the Atlas and Flair studies showed that along-acting, injectable two-drug regimen in HIV-1 patients had similar efficacy to a daily three-drug treatment. Both phase three studies assessed a long-acting, injectable combination of cabotegravir and rilpivirine - injected every four weeks - and compared it against a standard of care, daily, three-drug regimen. 48-week data from both studies shows that they met their primary endpoints, showing that the two-drug regimen was not inferior in treating HIV. John Pottage, chief scientific & medical officer Of ViiV Healcare said: "With Flair and Atlas, we now have positive results from two pivotal phase three studies demonstrating that this long-acting, once-monthly injectable regimen has similar efficacy, safety and tolerability to a daily oral three-drug regimen for the treatment of HIV."----------FTSE 100 - LOSERS----------GVC Holdings, down 18% at 563.65 pence. GVC Chair Lee Feldman and Chief Executive Kenneth Alexander sold a significant amount of stock. Alexander sold 2.1 million shares at 666 pence for GBP13.7 million, while Feldman disposed of 900,000 shares at the same price for GBP6.0 million. Alexander said: "We have both held large personal shareholdings in GVC for a long time and continue to do so. Both of us remain fully committed to GVC and, whilst I continue to have the support of our shareholders, I'm here for the long term and at the very least I have a current plan that will take three plus years to accomplish."----------FTSE 250 - WINNERS----------SIG, up 9.1%. The building products supplier reported a drop in annual revenue, though it swung to a pretax profit. SIG's statutory revenue fell to GBP2.74 billion in 2018, from GBP2.88 billion in 2017, but it returned to pretax profit, posting GBP28.5 million from a GBP54.7 million loss a year prior. On an underlying basis, revenue fell 1.2% to GBP2.68 billion, with like-for-like sales down 2.1%. SIG's underlying pretax profit was up 8.5% to GBP75.3 million. SIG is paying a 2.5p final dividend, meaning the total for 2018 is unchanged from the year before at 3.75p. The company said its transformation strategy is now beginning to take shape, with the second half of 2018 seeing "significant" progress.----------Bodycote, up 7.2%. The thermal processing firm reported solid revenue and profit growth for 2018, with all of its divisions managing to report revenue improvement. The firm's statutory pretax profit climbed to GBP132.2 million from GBP117.0 million, with the headline figure up 12% to GBP136.4 million. Bodycote's revenue rose 5.6%, and 6.7% at constant currency rates, to GBP728.6 million. The company will pay a final dividend of 13.2p, taking the 2018 total to 19.0p from 17.4p a year before. On top of that, it also will pay a special dividend of 20p, having returned a special payout of 25p in 2017. Bodycote had a strong year, the company said, and it enters 2019 "well positioned".----------FTSE 250 - LOSERS----------Saga, down 9.0%. JPMorgan downgraded Saga to Underweight from Neutral, saying a weak balance sheet, alongside heightened insurance industry competition, could lead to concerns about the over 50s travel and insurance services provider's dividend. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Panthera Resources, up 20%. The miner reported positive developments from an investee, including a "significant" acquisition. Panthera has a 17% stake in Anglo Saxony Mining, a European explorer and developer with a flagship tin project in Tellerhauser, Germany. ASM's purchase is the Gottesberg tin deposit, 28 kilometres to the west of Tellerhauser, paid with both cash and shares. Gottesberg has a total resource of 42.1 million tonnes of ore at a grade of 0.27% tin, suggesting 113,000 tonnes of the commodity. Combining Gottesberg and Tellerhauser's resources, ASM now has a resource of 217,000 ounces of tin, which Panthera said is among the largest in the world. ----------Debenhams, up 13%. The troubled department store chain said it is "disappointed" that Sports Direct International has decided to requisition a general meeting to appoint Sports Direct boss Mike Ashley to the Debenhams board and remove all but one current board member. Debenhams added it has been engaging with both Sports Direct and other stakeholders regarding options to restructure the company's balance sheet. Sports Direct late Thursday said Founder & Chief Executive Ashley is seeking appointment to Debehmans board of directors. Ashley is aiming to be appointed to an executive role to focus on Debenhams business, including building a strong board and management team. Furthermore, Sports Direct is seeking to oust all Debenhams' board members with the exception of Rachel Osborne, who became a director in September 2018. If appointed, Ashley would step down from his current roles as a director & CEO of Sports Direct, which was down 0.5%.----------OTHER MAIN MARKET AND AIM - LOSERS----------Goals Soccer Centres, down 28%. The five-a-side football pitch operator said it expects 2018 results to be "materially below" expectations following discovery of accounting errors. Goals explained that results for the full year are now expected to be "materially below expectations" and delayed from their originally planned reporting date of March 12. This follows the firm - alongside its auditors - having to resolve some "accounting errors". Goals emphasised that the "majority" of these expected accounting adjustments are "non-cash" in nature. Despite this, the changes would mean that the firm will have "exceeded one of its banking covenants". Goals is currently discussing with the bank to agree new, renegotiated facilities. For the first two months of 2019, Goals reported trading had been "strong" with an increases in like-for-like sales on the prior year in both the UK and US.----------

More News
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.